IQVIA Holdings Inc. $IQV Stock Bought by Ascent Group LLC

Ascent Group LLC grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 66.4% in the third quarter, Holdings Channel.com reports. The firm owned 5,219 shares of the medical research company’s stock after buying an additional 2,082 shares during the period. Ascent Group LLC’s holdings in IQVIA were worth $1,403,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Compass Financial Management LLC raised its holdings in shares of IQVIA by 31.9% in the third quarter. Compass Financial Management LLC now owns 157 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 38 shares in the last quarter. North Dakota State Investment Board increased its position in IQVIA by 0.8% during the 3rd quarter. North Dakota State Investment Board now owns 5,063 shares of the medical research company’s stock worth $1,361,000 after purchasing an additional 40 shares in the last quarter. Apella Capital LLC grew its stake in IQVIA by 4.7% in the third quarter. Apella Capital LLC now owns 1,235 shares of the medical research company’s stock worth $319,000 after purchasing an additional 55 shares in the last quarter. Breakwater Capital Group raised its position in shares of IQVIA by 3.2% during the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock worth $401,000 after buying an additional 64 shares in the last quarter. Finally, Fortitude Family Office LLC increased its holdings in shares of IQVIA by 17.2% in the 3rd quarter. Fortitude Family Office LLC now owns 443 shares of the medical research company’s stock valued at $119,000 after purchasing an additional 65 shares during the period. Institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other news, insider James G. Berkshire sold 2,668 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider directly owned 10,890 shares in the company, valued at $2,845,883.70. This represents a 19.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.70% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on IQV. Morgan Stanley boosted their target price on IQVIA from $240.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, September 17th. Deutsche Bank Aktiengesellschaft reduced their price target on IQVIA from $191.00 to $179.00 in a report on Thursday, October 15th. HSBC boosted their target price on IQVIA from $280.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, September 1st. Truist Financial upped their price target on shares of IQVIA from $329.00 to $346.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. Finally, Leerink Partners raised their price target on shares of IQVIA from $280.00 to $310.00 and gave the company an “outperform” rating in a research report on Thursday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $294.21.

IQVIA Stock Performance

Shares of NYSE IQV opened at $271.45 on Friday. The business has a fifty day simple moving average of $266.55 and a 200 day simple moving average of $211.03. The firm has a market capitalization of $44.74 billion, a price-to-earnings ratio of 32.98, a PEG ratio of 2.30 and a beta of 1.16. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $284.50. The company has a current ratio of 0.83, a quick ratio of 0.83 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.26 by $0.08. The company had revenue of $4.43 billion during the quarter, compared to the consensus estimate of $4.37 billion. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The firm’s quarterly revenue was up 8.0% on a year-over-year basis. During the same period in the previous year, the business earned $3.00 earnings per share. Sell-side analysts expect that IQVIA Holdings Inc. will post 11.53 EPS for the current year.

About IQVIA

IQVIA Holdings Inc provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products.

The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.